SRM College of Pharmacy, SRMIST, Kattankulathur, Chennai, Tamilnadu, India.
J Biochem Mol Toxicol. 2023 May;37(5):e23327. doi: 10.1002/jbt.23327. Epub 2023 Feb 19.
Majority of chemotherapeutic agents can elicit antitumor immunity and modulate the composition, density, function, and distribution of tumor infiltrating lymphocytes (TILs), to influence differential therapeutic responses and prognosis in cancer patients. The clinical success of these agents, particularly anthracyclines like doxorubicin, not only depends on their cytotoxic activity but also by the enhancement of pre-existing immunity primarily through induction of immunogenic cell death (ICD). However, resistance for the induction of ICD either intrinsic or acquired is a major hurdle for most of these drugs. To enhance ICD by these agents, it has become clear that blockade of adenosine production or its signaling need to be specifically targeted as they represent highly resistant mechanisms. Given the prominent role of adenosine mediated immunosuppression and resistance to ICD induction in tumor microenvironment, combination strategies that involve ICD induction and adenosine signaling blockade are further warranted. In the present study, we investigated the antitumor effect of caffeine and doxorubicin combination therapy against 3-MCA-induced and cell-line induced tumors in mice. Our results demonstrated significant tumor growth inhibition by the combination therapy of doxorubicin and caffeine against both carcinogen-induced and cell-line induced tumor models. In addition, significant T-cell infiltration and enhanced ICD induction evidenced by increased intratumoral calreticulin and HMGB1 levels, was observed in B16F10 melanoma mice. The possible mechanism behind the observed antitumor activity might be due to the enhanced ICD induction and subsequent T-cell infiltration by the combination therapy. To prevent the development of resistance and to enhance the antitumor activity of ICD inducing drugs like doxorubicin, combination with adenosine-A2A receptor pathway inhibitors like caffeine might be a potential strategy.
大多数化疗药物可以引发抗肿瘤免疫,并调节肿瘤浸润淋巴细胞(TILs)的组成、密度、功能和分布,从而影响癌症患者的治疗反应和预后。这些药物的临床成功不仅取决于其细胞毒性活性,还取决于通过诱导免疫原性细胞死亡(ICD)增强预先存在的免疫,特别是像多柔比星这样的蒽环类药物。然而,对于大多数这些药物来说,诱导 ICD 的内在或获得性耐药是一个主要障碍。为了增强这些药物的 ICD,很明显需要针对腺苷产生或其信号传导的阻断,因为它们代表了高度耐药的机制。鉴于腺苷介导的免疫抑制和对 ICD 诱导的耐药性在肿瘤微环境中的突出作用,涉及 ICD 诱导和腺苷信号阻断的联合策略是进一步需要的。在本研究中,我们研究了咖啡因和多柔比星联合治疗对 3-MCA 诱导和细胞系诱导的小鼠肿瘤的抗肿瘤作用。我们的结果表明,多柔比星和咖啡因联合治疗对致癌物诱导和细胞系诱导的肿瘤模型均具有显著的肿瘤生长抑制作用。此外,在 B16F10 黑色素瘤小鼠中观察到 T 细胞浸润显著增加和 ICD 诱导增强,表现为肿瘤内钙网蛋白和高迁移率族蛋白 B1 水平增加。观察到的抗肿瘤活性的可能机制可能是由于联合治疗增强了 ICD 诱导和随后的 T 细胞浸润。为了防止耐药性的发展并增强像多柔比星这样的 ICD 诱导药物的抗肿瘤活性,与腺苷-A2A 受体通路抑制剂如咖啡因联合可能是一种潜在的策略。